2-methoxyestradiol has been researched along with Carcinoma, Neuroendocrine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, X; Jiang, H; Jiang, W; Jiang, X; Lin, H; Qiao, H; Sun, X; Zhu, H | 1 |
1 other study(ies) available for 2-methoxyestradiol and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma.
Topics: 2-Methoxyestradiol; Active Transport, Cell Nucleus; Adult; Anilides; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Neuroendocrine; Cell Proliferation; Cell Survival; Estradiol; Female; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Isoenzymes; Ki-67 Antigen; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pyridines; Signal Transduction; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2016 |